Dupilumab as a treatment for a case of benign familial pemphigus
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20242272Keywords:
HHD, Dupilumab, GenodermatosisAbstract
Hailey-Hailey disease (HHD) is an uncommon autosomal dominant genodermatosis characterized by recurrent blistering eruptions primarily affecting intertriginous areas, leading to the formation of eroded, erythematous plaques within flexural skin folds. The condition significantly impairs quality of life due to the frequency of infections, exacerbated by the limited and often ineffective therapeutic options currently available for HHD. In this report, we present a compelling case of HHD successfully treated with dupilumab, highlighting remarkable improvement observed within just two weeks of initiating treatment with this novel therapeutic agent. This promising outcome underscores the potential of dupilumab in managing challenging cases of HHD and warrants further exploration in larger clinical trials.
Metrics
References
Daniel H, Jean B. Darier Disease and Hailey–Hailey Diseas. Dermatology, 5th ed, Elsevier, Amsterdam, NL. 2024;951-61.
Konstantinou MP, Krasagakis K. Benign Familial Pemphigus (Hailey-Hailey Disease). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/ books/NBK585136/. Accessed on 18 June 2024.
Kieffer J, Le Duff F, Montaudié H, Chiaverini C, Lacour JP, Passeron T. Treatment of Severe Hailey-Hailey Disease with Apremilast. JAMA Dermatol. 2018;154(12):1453-6.
Chen A, DaCunha M, Harms J. Adalimumab therapy used successfully for recalcitrant Hailey-Hailey disease. JAAD Case Rep. 2022;29:173-6.
Alzahrani N, Grossman-Kranseler J, Swali R, Fiumara K, Zancanaro P, Tyring S, Rosmarin D. Hailey-Hailey disease treated with dupilumab: a case series. Br J Dermatol. 2021;185(3):680-2.
Highlights of prescribing information. Dupixent dupilumab injection, for subcutaneous use. Highlights of prescribing information. Regeneron Pharmaceuticals. Inc./Sanofi-Aventis, US. LLC, 2017. Available at: https://www.accessdata. fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf. Accessed on 18 June 2024.
Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J Biol Chem. 2004;279(22):23357-63.